Back to Results
First PageMeta Content
Health / Medicine / Mark G. Lebwohl / Atopic dermatitis / Eczema


Icahn School of Medicine at Mount Sinai Awarded $2.7 Million from NIH to Investigate Novel Therapy for Eczema “Narrow Pathway”-Targeted Immune Therapy May Spare Patients from Side Effects New York, NY (PRWEB) Novembe
Add to Reading List

Document Date: 2013-11-25 17:40:15

Open Document

File Size: 137,07 KB

Share Result on Facebook

City

Westchester / Long Island / New York City / New York / /

Company

PRWEB / Dermatology Research Laboratories / YouTube / Facebook / /

Currency

USD / /

Facility

Dermatology Clinic / PRWeb Contact Information Mount Sinai Press Office The Mount Sinai Medical Center / The Rockefeller University / /

IndustryTerm

Online Web / online version / ambulatory network / online visibility tool / outpatient services / /

MedicalCondition

dermatology diseases / skin disorder / atopic dermatitis / severe atopic dermatitis / Eczema / severe itching / chronic inflammation / inflammation / rash / inflammatory diseases / asthma / /

MedicalTreatment

surgery / /

NaturalFeature

Mount Sinai / Sinai / /

Organization

National Institute of Health / Inpatient Consult Service / Mount Sinai Medical Center / Laboratory for Investigative Dermatology / Department of Dermatology / Icahn School of Medicine / Rockefeller University / Laboratory for Inflammatory Skin Diseases / Dermatopathology Division / Inpatient Consultative Service / /

Person

James G. Krueger / Mark Lebwohl / Emma Guttman / /

/

Position

first investigator / Professor and head / Professor and Chair / Professor of Dermatology / and Director / General / Associate Professor / /

PublishedMedium

U.S. News & World Report / /

URL

http /

SocialTag